Study 14 of 15Tirzepatide literatureBMJ (Clinical research ed.)Top journal2026
Tirzepatide and cardiovascular outcomes.
Not reported in abstract.
Where it sits
this study against the rest of the tirzepatide corpus3
Preclinical · this one
10
Observational
0
Open-label
0
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Tirzepatide corpus
DTirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.BMJ (Clinical research ed.) · 2026—BGenomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> mediated by a conjugative IncFII<sub>K2</sub> NDM-1 plasmid.Virulence · 2026 · n=1069 · 0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.HumanBSerious acute biliary reporting with glucagon-like peptide-1-based therapies versus sodium-glucose cotransporter-2 inhibitors in type 2 diabetesbiorxiv-preprint · 2026 · 1.36 reporting odds ratio (95% CI 1.06-1.75; P = 0.013)HumanBReal-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.Obesity pillars · 2026 · 90% (n=45/48) of PwO reported likelihood to recommend tirzepatide.HumanBChanges in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.europepmc · 2026 · Weight loss of approximately 5.5 kg, n=28, P<0.001.HumanBAnnual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.europepmc · 2026 · n=500 · Cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650 lower with tirzepatide 5 mg compared to semaglutide 1 mg.Human